pelcitoclax
Generic: Pelcitoclax
pelcitoclax: 2 clinical trials tracked.
pelcitoclax evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about pelcitoclax, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (2)
A Phase IB Study of Safety, Efficacy and Pharmacokinetic of Intravenously Administered Pelcitoclax (APG-1252) in Patients With Advanced Neuroendocrine Tumor
Primary endpoint: Maximum tolerated dose (MTD) determination
Interventionalopen2 targetStarted 2022-01Completion 2022-093 sites · ChinaAscentage Pharma Group Inc.
A Phase Ib Study of Safety and Efficacy of APG-1252 in Combination With Osimertinib (AZD9291) in EGFR TKI Resistant NSCLC Patients
Primary endpoint: Maximum Tolerated Dose (MTD)
Interventionalopen80 targetStarted 2019-07Completion 2026-064 sites · ChinaAscentage Pharma Group Inc.